课题基金 / 基金详情

THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES

THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES
神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究
批准号:
8930654
负责人:
CAROL E GREEN
金额:
$43.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-23 至 2015-04-22

项目摘要

项目成果

CAROL E GREEN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
(R,R’)-4’-methoxy-1-napthylfenoterol (MNF) is a candidate anticancer agent developed within IRP, NIA that has demonstrated activity across a number of cancer cell culture lines. Preliminary studies in rodents suggest that the agent may possess anticancer action at tolerable doses and support further evaluation of the agent. There is hence a requirement for larger drug amounts to continue preclinical evaluation of MNF as well as potential clinical evaluation. To support this, Task Order 17 is to synthesize no less than 2 kg of cGMP (clinical grade) MNF material.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IGF::OT::IGF TASK ORDER #001 PERFORMANCE AREA 1 MANAGEMENT AND OPERATIONS SUPPORT
  • 批准号:
    10685239
  • 项目类别:
  • 资助金额:
    $8.08万
  • 财政年份:
    2022
  • 负责人:
    CAROL E GREEN
  • 依托单位:
NON-CLINICAL SAFETY ASSESSMENT OF ORC-13661 TO SUPPORT AMINOGLYCOSIDE INDUCED HEARING LOSS INDICATION. ADDITIONAL FUNDS.
  • 批准号:
    10972986
  • 项目类别:
  • 资助金额:
    $6.57万
  • 财政年份:
    2022
  • 负责人:
    CAROL E GREEN
  • 依托单位:
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"
  • 批准号:
    10407923
  • 项目类别:
  • 资助金额:
    $36.25万
  • 财政年份:
    2021
  • 负责人:
    CAROL E GREEN
  • 依托单位:
IGF::OT::IGF Task Order #3, "Continuous Rodent and Non-Rodent Pharmacokinetic Assessments"
  • 批准号:
    10551988
  • 项目类别:
  • 资助金额:
    $24.96万
  • 财政年份:
    2021
  • 负责人:
    CAROL E GREEN
  • 依托单位:
海外基金